Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy

Clinical Infectious Diseases

Volumn 54, Issue 8, 2012, Pages 1187-1195

  Rottinghaus, Erin K ^a   Ugbena, Richard ^b   Diallo, Karidia ^a   Bassey, Orji ^b   Azeez, Aderemi ^c   Devos, Joshua ^a   Zhang, Guoqing ^a   Aberle Grasse, John ^a   Nkengasong, John ^a   Yang, Chunfu ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b GAP CDC Nigeria ^*  (Nigeria)

^c Ministry of Health of Nigeria   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRIED BLOOD SPOT TESTING; DRUG RESISTANCE; GENOTYPE; HEALTH CARE PLANNING; HOSPITAL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NIGERIA; PLASMA; PRIORITY JOURNAL; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD; DESICCATION; DRUG MONITORING; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; NIGERIA; SPECIMEN HANDLING; VIRAL LOAD;

EID: 84859034045     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis015     Document Type: Article

References (36)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report. Geneva, Switzerland: World Health Organization, 2010.
2. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13.
3. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2):15-23.
4. World Health Organization. WHO manual for HIV drug resistance testing using dried blood spot specimens. 2010. Available at: http://www. who.int/hiv/topics/drugresistance/dbs-protocol.pdf. Accessed 4 February 2012.
5. Comeau AM, Pitt J, Hillyer GV, et al. Early detection of human immunodeficiency virus on dried blood spot specimens: sensitivity across serial specimens. Women and Infants Transmission Study Group. J Pediatr 1996; 129:111-18.
6. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS. Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr 2005; 38:615-17.
7. Stevens W, Erasmus L, Moloi M, Taleng T, Sarang S. Performance of a novel human immunodeficiency virus (HIV) type 1 total nucleic acid-based real-time PCR assay using whole blood and dried blood spots for diagnosis of HIV in infants. J Clin Microbiol 2008; 46:3941-5.
8. Gwinn M, Pappaioanou M, George JR, et al. Prevalence of HIV infection in childbearing women in the United States. Surveillance using newborn blood samples. JAMA 1991; 265:1704-8.
9. Hoff R, Berardi VP, Weiblen BJ, Mahoney-Trout L, Mitchell ML, Grady GF. Seroprevalence of human immunodeficiency virus among childbearing women: estimation by testing samples of blood from newborns. N Engl J Med 1988; 318:525-30.
10. Monleau M, Butel C, Delaporte E, Boillot F, Peeters M. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. J Antimicrob Chemother 2010; 65:1562-6.
11. World Health Organization. Guidance on regulations for the transport of infectious substances 2011-2012. 2011. Available at: http://whqlibdoc. who.int/hq/2010/WHO-HSE-IHR-2010.8-eng.pdf. Accessed 4 February 2012.
12. Bertagnolio S, Soto-Ramirez L, Pilon R, et al. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 2007; 12:107-13.
13. Lira R, Valdez-Salazar H, Vazquez-Rosales G, et al. Genotypic testing for HIV-1 drug resistance using dried blood samples. Arch Virol 2010; 155:1117-25.
14. McNulty A, Jennings C, Bennett D, et al. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 2007; 45:517-21.
15. Yang C, McNulty A, Diallo K, et al. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol 2010; 48:3158-64.
16. Garrido C, Zahonero N, Fernandes D, et al. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 2008; 61:694-8.
17. Hallack R, Doherty LE, Wethers JA, Parker MM. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J Clin Virol 2008; 41:283-7.
18. Masciotra S, Garrido C, Youngpairoj AS, et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 2007; 21:2503-11.
19. Steegen K, Luchters S, Demecheleer E, et al. Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J Clin Microbiol 2007; 45:3342-51.
20. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, deMendoza C, Garcia-Lerma JG. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother 2008; 61:1217-20.
21. Ziemniak C, George-Agwu A, Moss WJ, Ray SC, Persaud D. A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J Virol Methods 2006; 136:238-47.
22. Zhou Z, Wagar N, DeVos JR, et al. Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS One 2011; 6:e28184.
23. Bussmann H, de la Hoz Gomez F, Roels TH, et al. Prevalence of transmitted HIV drug resistance in Botswana: lessons learned from the HIVDR-threshold survey conducted among women presenting for routine antenatal care as part of the 2007 national sentinel survey. AIDS Res Hum Retroviruses 2011; 27:365-72.
24. Kamoto K, Aberle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008; 13(Suppl 2):83-7.
25. Somi GR, Kibuka T, Diallo K, et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008; 13(Suppl 2):77-82.
26. Zhang J, Kang D, Fu J, et al. Surveillance of transmitted HIV type 1 drug resistance in newly diagnosed HIV type 1-infected patients in Shandong Province, China. AIDS Res Hum Retroviruses 2010; 26:99-103.
27. Nguyen DB, Bui HT, Wagar N, et al. HIV drug resistance threshold survey using matched plasma and DBS specimens from voluntary counseling and testing sites in Ho Chi Minh City, Vietnam, 2007-2008. Clin Infect Dis 2012; doi:10.1093/cid/cir1049.
28. National AIDS/STDs Control Program FMoH. National guideline for HIV and AIDS treatment and care in adolescents and adults. Abuja, Nigeria: Federal Ministry of Health, 2007.
29. Ugbena R, Aberle-Grasse J, Diallo K, et al. Virological response and HIV-1 drug resistance development profile among patients treated with first-line antiretroviral regimens in Nigeria. 2012; doi:10.1093/cid/cir1064.
30. Biomerieux. NucliSENS EasyQ HIV-1 v1.1 RUO [package insert] Durham, NC: bioMérieux, Inc., 2007.
31. Johannessen A, Garrido C, Zahonero N, et al. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis 2009; 49:976-81.
32. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-10.
33. Fleiss JL, ed. Statistical methods for rates and proportions. 2nd ed. New York, NY: John Wiley, 1981.
34. Buckton AJ, Bissett SL, Myers RE, et al. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J Antimicrob Chemother 2008; 62:1191-8.
35. Kaye S, Comber E, Tenant-Flowers M, Loveday C. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses 1995; 11:1221-5.
36. Garcia-Lerma JG, McNulty A, Jennings C, Huang D, Heneine W, Bremer JW. Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity. J Antimicrob Chemother 2009; 64:33-6.